Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Project description

Novel drug combination treatment for tuberculosis

Tuberculosis (TB) is still the world's most deadly infectious disease, and multidrug-resistant TB poses a serious threat to global health. Treatment options are limited and often associated with many adverse effects from the drugs. The overall objective of the EU-funded RespiriTB project is to find new drug candidates for efficient combination treatment against TB and multidrug-resistant TB. The drug combination will target the energy metabolism of Mycobacterium tuberculosis (Mtb), using recently discovered inhibitors of the Mtb respiratory pathway. It will also target host factors that are essential for the intracellular survival of Mtb. The project presents a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce incidences of drug resistance.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance
• medical and health sciences › clinical medicine › pneumology › tuberculosis

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
• H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s)

• IMI2-2018-16-01 - Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Call for proposal

H2020-JTI-IMI2-2018-16-single-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

Address

Albinusdreef 2
2333 ZA Leiden
Netherlands

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 968 282,50

Participants (8)

UNIVERSITEIT LEIDEN

Netherlands

EU contribution

€ 124 375

Address

Rapenburg 70
2311 EZ Leiden

Activity type

Higher or Secondary Education Establishments

UNIVERSITEIT ANTWERPEN

Belgium

EU contribution

€ 4 179 723,34

Address

Prinsstraat 13
2000 Antwerpen

Activity type

Higher or Secondary Education Establishments

SORBONNE UNIVERSITE

France

EU contribution

€ 343 875

Address

21 Rue De L'ecole De Medecine
75006 Paris

Activity type

Higher or Secondary Education Establishments

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU contribution

€ 813 125

Address

Spitalgasse 23
1090 Wien

Activity type

Higher or Secondary Education Establishments

KOBENHAVNS UNIVERSITET

Denmark

EU contribution

€ 99 638,53

Address

Norregade 10
1165 Kobenhavn

Activity type

Higher or Secondary Education Establishments

JANSSEN PHARMACEUTICA NV

Belgium

EU contribution

€ 0

Address

Turnhoutseweg 30
2340 Beerse

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

MITOLOGICS

France

EU contribution

€ 146 630,63

Address

Avenue Gaston Roussel 102
93230 Romainville

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

FFUND BV

Netherlands

EU contribution

€ 164 350

Address

Hollandse Kade 32
1391 JM Abcoude

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)